Patents and licenses on antiretrovirals: a snapshot
HIV and congenital syphilis diagnostics technology landscape
The Trans-Pacific Partnership Agreement: [full report] Unitaid
The Trans-Pacific Partnership Agreement: implications for access to medicines and public health [executive summary], Unitaid
HIV/AIDS medicines technology and market landscape – 1st edition
Key Performance Indicators 2014
Patent landscape, delamanid (OPC-67683)
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Meeting report
Accelerating access to innovative point-of-care HIV diagnostics: Lessons learned from UNICEF
Innovative delivery systems for paediatric medicines technology landscape
Disease Narrative for hepatitis C
Disease narrative for tuberculosis
Disease Narrative for malaria
Disease Narrative for HIV
Hepatitis C diagnostics technology landscape – May 2019
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Financial Guidelines for Unitaid Grant Implementers (Frequently Asked Questions)
Unitaid 2017-2021 Strategy Review, Management Response, Dec 2021
Unitaid 2017-2021 Strategy Review, Final Report, Vol 2, Annexes
Unitaid 2017-202 Strategy Review, Final Report, Vol 1, Main report
Financial guidelines for Unitaid grant implementers
Financial Guidelines for Unitaid Grantees
Landscape for HIV rapid diagnostic tests for HIV self-testing – 2020
Impact story: Paving the way to hepatitis C elimination
